CGCFFinancial Services · Shell Companies

CGCF Stock Forecast: Cartesian Growth Corp. IV Price Predictions for 2026-2027

Last close, 24 Aug 2026
$9.86
−0.15% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$342.4M
Ticker Nerd rank
7 / 100
Median analyst target
Analysts covering
Total return, dividends reinvested
1W
−1.2%
From high
−1.2%
From low
+0.4%
$9.82
$9.97
Range since 17 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

CGCF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cartesian Growth Corp. IV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
7 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
60
Volatility
59
Value
45
Revisions
25
Quality
24
Momentum
22
Growth
16
Issuance
14
Accruals
8

Size (60): Smaller than most of the companies we track.

Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGCF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGCF, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGCF appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CGCF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cartesian Growth Corp. IV (CGCF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
Price / sales
Price / book
EV / EBITDA
Growth & margins
Revenue growth (YoY)
Earnings growth (YoY)
Gross margin
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
Return on assets
Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cartesian Growth Corp. IV (CGCF) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cartesian Growth Corp. IV has a market value of $342.4M and an enterprise value of $342.8M.

  • Shares outstanding: 27.5M.

  • Cartesian Growth Corp. IV employs 0 people.

market figures as at 23 Aug 2026

Data provided by Twelve Data

Peers

CGCF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelShell Companies
CompanyMarket capTKN rank
CGCFCartesian Growth Corp. IV$342.4M
7
AACIArmada Acquisition Corp. III$341.7M
14
GUACBerto Acquisition Corp. II$341.5M
7
IPFXInflection Point Acquisition Corp. VI$341.0M
9
FGIIFG Imperii Acquisition Corp.$345.9M
13
SORNSoren Acquisition Corp.$345.9M
13
DSACDaedalus Special Acquisition Corp.$346.0M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cartesian Growth Corp. IV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Frequently asked questions about CGCF stock

How does Ticker Nerd's model rank CGCF?

As at 22 Aug 2026, Cartesian Growth Corp. IV ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (60 of 100).

What is the CGCF stock forecast for 2030?

No analyst covering Cartesian Growth Corp. IV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGCF are extrapolating price history, which says nothing about the business.

What does Cartesian Growth Corp. IV do?

Cartesian Growth Corporation IV Class A Ordinary Shares represent the public equity of Cartesian Growth Corporation IV, a blank check company formed to pursue a business combination with one or more operating businesses. The Class A ordinary shares are part of the company’s capital structure alongside its warrants and units, and they provide public investors with an equity interest in the vehicle while it evaluates merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar transaction opportunities.

Company

About Cartesian Growth Corp. IV.

Cartesian Growth Corporation IV Class A Ordinary Shares represent the public equity of Cartesian Growth Corporation IV, a blank check company formed to pursue a business combination with one or more operating businesses. The Class A ordinary shares are part of the company’s capital structure alongside its warrants and units, and they provide public investors with an equity interest in the vehicle while it evaluates merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar transaction opportunities. Cartesian Growth Corporation IV is based in New York and operates as a special purpose acquisition company, a structure commonly used in the public markets to raise capital for future combination activity. The shares are designed to trade separately from the company’s units once the securities are split, making them a distinct instrument within the company’s listed securities set.

CEO Dr. Peter Michael Yu Ph.D. · United States